SARS vaccine development.

Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.

[1]  S. Jiang,et al.  Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41 [published erratum appears in J Exp Med 1992 Feb 1;175(2):621] , 1991, The Journal of experimental medicine.

[2]  Y. Guan,et al.  Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice , 2004, Vaccine.

[3]  E. Marshall,et al.  Medicine. Caution urged on SARS vaccines. , 2004, Science.

[4]  R. Proulx,et al.  Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets , 2004, Journal of Virology.

[5]  Shibo Jiang,et al.  Enhancement of Human Immunodeficiency Virus Type 1 lnCection by Antisera to Peptides from the Envelope Glycoproteins gp120/gp41 , 2003 .

[6]  Shixia Wang,et al.  Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) , 2005, Virology.

[7]  Jiahai Lu,et al.  Glycan arrays lead to the discovery of autoimmunogenic activity of SARS-CoV , 2004, Physiological genomics.

[8]  Larissa B. Thackray,et al.  CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Dimitrov,et al.  The SARS-CoV S glycoprotein: expression and functional characterization , 2003, Biochemical and Biophysical Research Communications.

[10]  H. Doerr,et al.  Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus , 2005, Journal of Virology.

[11]  Shibo Jiang,et al.  Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine , 2004, Biochemical and Biophysical Research Communications.

[12]  Sheng Xiong,et al.  Immunogenicity of SARS inactivated vaccine in BALB/c mice , 2004, Immunology Letters.

[13]  Wenhui Li,et al.  A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2* , 2004, Journal of Biological Chemistry.

[14]  Shibo Jiang,et al.  Identification of Immunodominant Sites on the Spike Protein of Severe Acute Respiratory Syndrome (SARS) Coronavirus: Implication for Developing SARS Diagnostics and Vaccines , 2004, The Journal of Immunology.

[15]  Shixia Wang,et al.  Identification of Two Neutralizing Regions on the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Produced from the Mammalian Expression System , 2005, Journal of Virology.

[16]  Sung Keun Kang,et al.  Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. , 2004, Science.

[17]  Y. Guan,et al.  Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage , 2003, Journal of Molecular Biology.

[18]  Shibo Jiang,et al.  Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry , 2004, Biochemical and Biophysical Research Communications.

[19]  A. Debnath,et al.  Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.

[20]  G. Gao,et al.  Crystal Structure of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fusion Core* , 2004, Journal of Biological Chemistry.

[21]  L. Saif,et al.  Identification of antigenic sites mediating antibody-dependent enhancement of feline infectious peritonitis virus infectivity. , 1993, The Journal of general virology.

[22]  B. Murphy,et al.  Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS , 2004, The Lancet.

[23]  Y. Guan,et al.  Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome , 2004, The Lancet.

[24]  Kwanyee Leung,et al.  Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Danchin,et al.  The Severe Acute Respiratory Syndrome , 2003 .

[26]  D. Dimitrov.  The Secret Life of ACE2 as a Receptor for the SARS Virus , 2003, Cell.

[27]  K. Subbarao,et al.  pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN , 2004, Journal of Virology.

[28]  K. Holmes,et al.  SARS-associated coronavirus. , 2003, The New England journal of medicine.

[29]  J. Peiris,et al.  Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS) , 2003, The Lancet.

[30]  Zhihong Guo,et al.  B-Cell Responses in Patients Who Have Recovered from Severe Acute Respiratory Syndrome Target a Dominant Site in the S2 Domain of the Surface Spike Glycoprotein , 2005, Journal of Virology.

[31]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[32]  E. Marshall,et al.  Caution Urged on SARS Vaccines , 2004, Science.

[33]  R. Hodges,et al.  Structural Characterization of the SARS-Coronavirus Spike S Fusion Protein Core , 2004, Journal of Biological Chemistry.

[34]  B. Moss,et al.  Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[36]  Shibo Jiang,et al.  Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies , 2005, The Journal of Immunology.

[37]  Baoan Yang,et al.  Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines , 2005, Virology.

[38]  Guoping Zhao,et al.  Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China , 2004, Science.

[39]  D. Ho,et al.  Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region , 2005, Journal of Virology.

[40]  X. L. Liu,et al.  Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.

[41]  W. Hong,et al.  Amino Acids 1055 to 1192 in the S2 Region of Severe Acute Respiratory Syndrome Coronavirus S Protein Induce Neutralizing Antibodies: Implications for the Development of Vaccines and Antiviral Agents , 2005, Journal of Virology.

[42]  D. Dimitrov,et al.  A model of the ACE2 structure and function as a SARS-CoV receptor , 2003, Biochemical and Biophysical Research Communications.